Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 52

Sort by

Sort Order Select

Journal Articles

Exploring Red Blood Cells As an Antigen Delivery System to Modulate the Immune Response Towards FVIII in Hemophilia a

Mariarosaria Miranda, Eelke Bradsma, Lotte Robben, Helena Van Dender, Floris Van Alphen, Karin Fijnvandraat, Maartje van den Biggelaar, Sebastien Lacroix-Desmazes, Robin van Bruggen, J. J. Voorberg

Blood (2024) 144 (Supplement 1): 5476.

https://doi.org/10.1182/blood-2024-203336

Published: 2024

Journal Articles

Spleen Function and Infections in the Youngest Patients with Sickle Cell Disease in the Netherlands

Cornelis R Van Der Torren, Celine H.A. Rook, Nimue van Valderen, Lydian A. De Ligt, Robin van Bruggen, Karin Fijnvandraat

Blood (2024) 144 (Supplement 1): 5334.

https://doi.org/10.1182/blood-2024-193745

Published: 2024

Journal Articles

Oxygen Gradient Ektacytometry Is Associated with Markers of Hemolysis and Inflammation in a Large Sickle Cell Disease Cohort within the GenoMed4ALL Project

Blood (2024) 144 (Supplement 1): 290.

https://doi.org/10.1182/blood-2024-200639

Published: 2024

Journal Articles

Data Driven Research through the European RADeep Registry and the Use of Artificial Intelligence Towards Personalized Medicine in Sickle Cell Disease

Blood (2024) 144 (Supplement 1): 1138.

https://doi.org/10.1182/blood-2024-203331

Published: 2024

Journal Articles

Alterations in the Immune Phenotype of Adaptive Immune Cells in Sickle Cell Disease: A Conventional and Computational Flow Cytometry Analysis

Elisabeth Dovern, Tim R. Mocking, Mette D. Hazenberg, Cornelis R van der Torren, Boukje M. Beuger, Robin van Bruggen, Simon Tol, Erik Mul, Marjolein van der Pot, Arjan A. van de Loosdrecht, Myrddin Verheij, Karin Fijnvandraat, Carlijn Voermans, Bart J. Biemond, Costa Bachas, Erfan Nur

Blood (2024) 144 (Supplement 1): 2483.

https://doi.org/10.1182/blood-2024-194363

Published: 2024

Journal Articles

Clinical Outcomes over 2 Years of Once-Weekly Efanesoctocog Alfa Treatment in Children with Severe Hemophilia A: Second Interim Analysis from the Phase 3 XTEND-ed Long-Term Extension Study

Lynn Malec, Beatrice Nolan, Anthony K C Chan, Manuela Albisetti, Sheng-Chieh Chou, Bulent Zulfikar, Mindy Simpson, Liqi Feng, Helena Palmborg, Graham Neill, Lydia Abad-Franch, Sriya Gunawardena, Karin Fijnvandraat

Blood (2024) 144 (Supplement 1): 5495.

https://doi.org/10.1182/blood-2024-206915

Published: 2024

Journal Articles

Type 1 VWD classification revisited: novel insights from combined analysis of the LoVIC and WiN studies

Blood (2024) 143 (14): 1414–1424.

https://doi.org/10.1182/blood.2023022457

Published: 2024

Includes: Supplemental data

Journal Articles

Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial

Steven W. Pipe, Peter Collins, Christophe Dhalluin, Gili Kenet, Christophe Schmitt, Muriel Buri, Víctor Jiménez-Yuste, Flora Peyvandi, Guy Young, Johannes Oldenburg, Maria Elisa Mancuso, Kaan Kavakli, Anna Kiialainen, Sonia Deb, Markus Niggli, Tiffany Chang, Michaela Lehle, Karin Fijnvandraat

Blood (2024) 143 (14): 1355–1364.

https://doi.org/10.1182/blood.2023021832

Published: 2024

Includes: Supplemental data

Journal Articles

Plasma Proteome Profiling of Sickle Cell Patients Reveals Activation of Inflammatory Pathways during Steady State and Vaso-Occlusive Crisis

Lydian A. de Ligt, Aafke E. Gaartman, Kadère Konté, Taco W. Kuijpers, Karin Fijnvandraat, Bart J. Biemond, Robin van Bruggen, Erfan Nur

Blood (2023) 142 (Supplement 1): 1108.

https://doi.org/10.1182/blood-2023-179239

Published: 2023

Journal Articles

Age Regulates Desmopressin Responses in Patients with Low Von Willebrand Factor and Type 1 Von Willebrand Disease in the Lovic and Win Studies

Blood (2023) 142 (Supplement 1): 510.

https://doi.org/10.1182/blood-2023-184734

Published: 2023

Journal Articles

The Relationship between Low Von Willebrand Factor, Type 1 Von Willebrand Disease and Ageing - Novel Insights from the Lovic and Win Cohort Studies

Blood (2023) 142 (Supplement 1): 509.

https://doi.org/10.1182/blood-2023-181603

Published: 2023

Journal Articles

Emicizumab Prophylaxis in Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Primary Analysis of the HAVEN 7 Study

Steven Pipe, Peter Collins, Christophe Dhalluin, Gili Kenet, Christophe Schmitt, Muriel Buri, Víctor Jiménez-Yuste, Flora Peyvandi, Guy Young, Johannes Oldenburg, Maria Elisa Mancuso, Kaan Kavakli, Anna Kiialainen, Tiffany Chang, Michaela Lehle, Markus Niggli, Karin Fijnvandraat

Blood (2023) 142 (Supplement 1): 505.

https://doi.org/10.1182/blood-2023-177963

Published: 2023

Journal Articles

Use of Machine Learning to Predict 30-Day Reutilization of Care for Patients with Sickle Cell Disease Treated for Vaso-Occlusive Crisis

Caroline Vuong, Kumar Utkarsh, Rebecca Stojancic, Arvind Mallikarjunan, Olivia Fernandez, Tanvi Banerjee, Daniel A. Abrams, Karin Fijnvandraat, Nirmish Shah

Blood (2023) 142 (Supplement 1): 3896.

https://doi.org/10.1182/blood-2023-186272

Published: 2023

Journal Articles

Pharmacodynamic Biomarkers in Infants with Hemophilia A Receiving Emicizumab in HAVEN 7

Anna Kiialainen, Steven Pipe, Karin Fijnvandraat, Gili Kenet, Christophe Schmitt, Muriel Buri, Víctor Jiménez-Yuste, Johannes Oldenburg, Maria Elisa Mancuso, Christophe Dhalluin, Michaela Lehle, Peter Collins

Blood (2023) 142 (Supplement 1): 1238.

https://doi.org/10.1182/blood-2023-173015

Published: 2023

Journal Articles

Analysis of Volatile Organic Compounds in Exhaled Air in Patients with Sickle Cell Disease during Vaso-Occlusive Episodes

Caroline Vuong, Paul Brinkman, Harriët Heijboer, Erfan Nur, Cornelia De Groot - Eckhardt, Suzanne W.J. Terheggen-Lagro, Bart J. Biemond, Anke-Hilse Maitland-van der Zee, Karin Fijnvandraat

Blood (2023) 142 (Supplement 1): 1131.

https://doi.org/10.1182/blood-2023-180835

Published: 2023

Journal Articles

National Long-Term Follow-up of Children with Sickle Cell Disease Diagnosed By Newborn Screening in the Netherlands: Overview of the Morbidity and Mortality

Caroline Vuong, Cornelia De Groot - Eckhardt, Harriët Heijboer, Monique H. Suijker, Lydian A. De Ligt, Marije Bartels, Paul Brons, Louise Hooimeijer, Eva Rettenbacher, Frans J. Smiers, Marjet A. Stein-Wit, Arian van der Veer, Annemieke Verbaan, Marjon H. Cnossen, Karin Fijnvandraat

Blood (2023) 142 (Supplement 1): 3891.

https://doi.org/10.1182/blood-2023-179802

Published: 2023

Journal Articles

Colorectal Cancer Screening in Patients with Inherited Bleeding Disorders: High Cancer Detection Rate in Hemophilia Patients

Eva Kempers, Calvin B. van Kwawegen, Joke de Meris, Saskia E.M. Schols, Paula F. Ypma, Floor C.J.I. Moenen, Lize F.D. Van Vulpen, Michiel Coppens, Johanna G. van der Bom, Karin Fijnvandraat, Karina Meijer, Jeroen C.J. Eikenboom, Samantha C. Gouw, Frank W.G. Leebeek, Marieke J.H.A. Kruip

Blood (2022) 140 (Supplement 1): 1416–1417.

https://doi.org/10.1182/blood-2022-157537

Published: 2022

Journal Articles

The Impact of Hospital Admission for Vaso-Occlusive Crisis on Health-Related Quality of Life in Children with Sickle Cell Disease

Caroline Vuong, Ibtissame Moussa, Lotte Haverman, Eva Rettenbacher, Harriet Heijboer, Jos W.R. Twisk, Karin Fijnvandraat, Corien L. Eckhardt

Blood (2022) 140 (Supplement 1): 13145.

https://doi.org/10.1182/blood-2022-163291

Published: 2022

Journal Articles

Long-Term Follow-up of Dutch Patients with Sickle Cell Disease Diagnosed By Newborn Screening - Effect on the Morbidity and Mortality in the Netherlands

Caroline Vuong, Corien L. Eckhardt, Lydian de Ligt, Harriet Heijboer, Eva Rettenbacher, Arian van der Veer, Marjet Stein-Wit, Paul Brons, Frans J. Smiers, Monique Suijker, Marjon H. Cnossen, Karin Fijnvandraat

Blood (2022) 140 (Supplement 1): 2562–2563.

https://doi.org/10.1182/blood-2022-163100

Published: 2022

Journal Articles

Emicizumab Prophylaxis for the Treatment of Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Interim Analysis of the HAVEN 7 Study

Steven W. Pipe, Peter Collins, Christophe Dhalluin, Gili Kenet, Christophe Schmitt, Muriel Buri, Víctor Jiménez-Yuste, Flora Peyvandi, Guy Young, Johannes Oldenburg, Maria Elisa Mancuso, Anna Kiialainen, Tiffany Chang, Michaela Lehle, Karin Fijnvandraat

Blood (2022) 140 (Supplement 1): 457–459.

https://doi.org/10.1182/blood-2022-157264

Published: 2022

NARROW

Exploring Red Blood Cells As an Antigen Delivery System to Modulate the Immune Response Towards FVIII in Hemophilia a

Spleen Function and Infections in the Youngest Patients with Sickle Cell Disease in the Netherlands

Oxygen Gradient Ektacytometry Is Associated with Markers of Hemolysis and Inflammation in a Large Sickle Cell Disease Cohort within the GenoMed4ALL Project

Data Driven Research through the European RADeep Registry and the Use of Artificial Intelligence Towards Personalized Medicine in Sickle Cell Disease

Alterations in the Immune Phenotype of Adaptive Immune Cells in Sickle Cell Disease: A Conventional and Computational Flow Cytometry Analysis

Clinical Outcomes over 2 Years of Once-Weekly Efanesoctocog Alfa Treatment in Children with Severe Hemophilia A: Second Interim Analysis from the Phase 3 XTEND-ed Long-Term Extension Study

Type 1 VWD classification revisited: novel insights from combined analysis of the LoVIC and WiN studies

Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial

Plasma Proteome Profiling of Sickle Cell Patients Reveals Activation of Inflammatory Pathways during Steady State and Vaso-Occlusive Crisis

Age Regulates Desmopressin Responses in Patients with Low Von Willebrand Factor and Type 1 Von Willebrand Disease in the Lovic and Win Studies

The Relationship between Low Von Willebrand Factor, Type 1 Von Willebrand Disease and Ageing - Novel Insights from the Lovic and Win Cohort Studies

Emicizumab Prophylaxis in Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Primary Analysis of the HAVEN 7 Study

Use of Machine Learning to Predict 30-Day Reutilization of Care for Patients with Sickle Cell Disease Treated for Vaso-Occlusive Crisis

Pharmacodynamic Biomarkers in Infants with Hemophilia A Receiving Emicizumab in HAVEN 7

Analysis of Volatile Organic Compounds in Exhaled Air in Patients with Sickle Cell Disease during Vaso-Occlusive Episodes

National Long-Term Follow-up of Children with Sickle Cell Disease Diagnosed By Newborn Screening in the Netherlands: Overview of the Morbidity and Mortality

Colorectal Cancer Screening in Patients with Inherited Bleeding Disorders: High Cancer Detection Rate in Hemophilia Patients

The Impact of Hospital Admission for Vaso-Occlusive Crisis on Health-Related Quality of Life in Children with Sickle Cell Disease

Long-Term Follow-up of Dutch Patients with Sickle Cell Disease Diagnosed By Newborn Screening - Effect on the Morbidity and Mortality in the Netherlands

Emicizumab Prophylaxis for the Treatment of Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Interim Analysis of the HAVEN 7 Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only